EWTX · Edgewise Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $151.39M | $126.97M | $90.91M | $54.03M | $14.98M |
| SG&A | $40.02M | $31.87M | $23.45M | $17.63M | $2.21M |
| Total Operating Expenses | $191.41M | $158.83M | $114.36M | $71.66M | $17.19M |
| D&A | $2.08M | $2.07M | $1.55M | $368.0K | $185.0K |
| Operating Income | ($191.41M) | ($158.83M) | ($114.36M) | ($71.66M) | ($17.19M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | $4.0K | $0 | $0 | $0 | $0 |
| Net Income | ($167.79M) | ($133.81M) | ($100.16M) | ($67.64M) | ($17.12M) |
| EPS - Basic | ($1.63) | ($1.45) | ($1.57) | ($1.26) | ($23.17) |
| EPS - Diluted | ($1.63) | ($1.45) | ($1.57) | ($1.26) | ($23.17) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $61.15M | $41.67M | $86.10M | $21.99M | $15.57M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $6.01M | $5.58M | $4.03M | $6.11M | $3.84M |
| Current Assets | $543.38M | $475.48M | $327.00M | $357.00M | $283.77M |
| Total Assets | $552.60M | $486.82M | $340.04M | $367.10M | $285.23M |
| Current Liabilities | $27.37M | $23.86M | $16.77M | $16.59M | $10.52M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $30.35M | $27.60M | $21.20M | $20.39M | $10.85M |
| Stockholders' Equity | $522.26M | $459.22M | $318.83M | $346.72M | $274.38M |
| Retained Earnings | ($546.37M) | ($378.58M) | ($244.76M) | ($144.60M) | ($76.96M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($143.82M) | ($109.03M) | ($91.95M) | ($52.63M) | ($14.63M) |
| Investing Cash Flow | ($32.79M) | ($184.66M) | $102.89M | ($70.58M) | ($24.38M) |
| Financing Cash Flow | $196.09M | $249.25M | $53.17M | $129.64M | $120.28M |
| CapEx | $256.0K | $1.31M | $5.75M | $5.55M | $203.0K |
| Free Cash Flow | ($144.07M) | ($110.34M) | ($97.69M) | ($58.18M) | ($14.84M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | 0.86 | 0.82 | 0.98 | 0.86 | 0.87 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -30.4% | -27.5% | -29.5% | -18.4% | -6.0% |
| Return on equity | -32.1% | -29.1% | -31.4% | -19.5% | -6.2% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 19.85 | 19.93 | 19.50 | 21.53 | 26.97 |
| Quick ratio | 19.85 | 19.93 | 19.50 | 21.53 | 26.97 |
| Cash ratio | 2.23 | 1.75 | 5.13 | 1.33 | 1.48 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 1.06 | 1.06 | 1.07 | 1.06 | 1.04 |
| Liabilities / Assets | 0.05 | 0.06 | 0.06 | 0.06 | 0.04 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 4.9x | 5.4x | 2.2x | 1.4x | 0.0x |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -20.5% | -38.9% | -59.6% | -316.8% | - |
| Net income growth (YoY) | -25.4% | -33.6% | -48.1% | -295.0% | - |
| EPS growth (YoY) | -12.4% | 7.6% | -24.6% | 94.6% | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -30.6% | -12.9% | -67.9% | -292.1% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 13.7% | 44.0% | -8.0% | 26.4% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Edgewise Therapeutics against the 5 most active filers in the same SIC group.